Latest Lead News

Cambium Bio has raised A$2.12 million through a fully subscribed placement led by Taiwanese institutional investor Da Jyun Capital, supporting the initiation of pivotal Phase 3 trials for its lead ophthalmology candidate.

Citigold Corporation Limited reports steady progress in exploration and mine design at its Charters Towers Gold Project, while actively pursuing funding partnerships to restart operations.

Lode Resources reports strong assay results from its Montezuma Antimony & Silver Project and announces a maiden resource estimate at Webbs Consol, while advancing drilling at its Magwood Antimony Project.

Jatcorp Limited reported a robust 76% revenue increase in Q4 FY25, driven by strong Moroka® sales and expanded manufacturing capabilities, setting ambitious growth targets for FY26.

Altech Batteries confirms the safety and durability of its CERENERGY® sodium-nickel-chloride battery technology through rigorous testing, while its Silumina Anodes™ pilot plant in Germany achieves a 50% capacity increase. An independent DNV study endorses the technology’s promising future.

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

Codeifai Limited has raised $2.35 million through a share placement to fund key acquisitions and expand its footprint in quantum computing and AI. The move signals a strategic push towards U.S. market engagement and commercialisation of cutting-edge technology.

Uscom Limited reported a significant revenue decline in Q4 2025 amid global market instability but is focusing on cost management and strategic partnerships to position for recovery.

CAQ Holdings reported a significant 35% decline in leasing revenue for the June 2025 quarter amid tenant contract changes and high vacancy rates. The company is optimistic about a turnaround following new customs policies in Hainan Free Trade Port set to take effect in December.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

Investigator Resources is advancing its South Australian silver projects with planned drilling at the Athena Prospect and inaugural copper-gold drilling at Curnamona, backed by a recent $4.3 million capital raise and new leadership.